An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA.
GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront
A pharmacy benefit manager has thrown a legal punch at the Federal Trade Commission (FTC), taking issue with the agency's recent report accusing PBMs of using anti-competitive practices to
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo